Pharma prices continue to rise in the US – or do they?
Governments have used lowered pricing as one strategy to reduce expenditures, among others, and therefore the pharmaceutical industry remains under…
By
Pricing and Market Access
Latest in
Pricing and Market Access
2021: a record year for orphan therapies
In this blog, the Poli team looks back at the 2021 pricing and reimbursement trends in the orphan drug space…
By
China’s latest NRDL update continues to exclude foreign PD-1 inhibitors, favours rare disease drugs
China’s much-anticipated update of its National Reimbursement Drug List (NRDL) presents a mixed bag for overseas pharma. Overall, there were…
By
Seven years on ICER’s review process remains unpredictable
The US Institute for Clinical and Economic Review (ICER) began publishing health technology assessments (HTAs) for innovative medicines in 2014…
By
The Unitary Patent and the Unified Patent Court: possible opening in second half of 2022 will mean a complex European patent patchwork
A unified system of European patents has been a goal of those working towards European integration since before the establishment…
By
Brazil finally edges towards first drug pricing reform after two years – is it a missed opportunity?
In our recent blog on trends in international reference pricing (IRP), we mentioned that a public consultation was underway in Brazil on…
By
Will IRP upend Czech orphan drug reforms?
On 14 September, the Czech Chamber of Deputies gave its final approval to the amendment of the Public Health Insurance…
By Variations on an IRP theme: How payers are repurposing pricing policies for new categories of medicines
"Don't reinvent the wheel." "If it ain't broke, don't fix it." These are adages as old as time. And they…
By